Urticaria
Drug research and approvals for urticaria: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 60 studies of urticaria are recruiting on ClinicalTrials.gov, Health Canada has authorized 32 drug trials for it since 2013, FDA has 0 approved and 1 open orphan designations naming it, and the EU has 8 authorised medicines for it.
- Recruiting worldwide: 60
- Trials authorized in Canada: 32
- FDA orphan approvals: 0
- EU medicines: 8
- A Study of NN2802, an Anti-c-Kit Antibody, in Healthy Participants and in Adults With Chronic Spontaneous Urticaria…NCT07930572 · Phase 1 / Phase 2 · Novelty Nobility, Inc. · starts Oct 15, 2026
- Characteristics and Management of Patients With Severe Chronic Spontaneous and/or Inducible Urticaria Refractory to…NCT07833696 · Not reported · Centre Hospitalier Universitaire de Besancon · starts Jan 1, 2020
- Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous…NCT07816328 · Phase 3 · Novartis Pharmaceuticals · starts Sep 21, 2026
- A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU)NCT07766499 · Phase 2 · Calixis Inc. · starts Sep 15, 2026
- Mediterranean and Low-Histamine Diets for Pediatric Chronic Spontaneous UrticariaNCT07765979 · Not applicable · Saglik Bilimleri Universitesi · starts Nov 23, 2025
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity…NCT07717905 · Phase 1 / Phase 2 · Bambusa Therapeutics · starts Jun 29, 2026
- Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With…NCT07654829 · Phase 4 · KalVista Pharmaceuticals, Ltd. · starts Aug 17, 2026
- Trial to Test the Efficacy of Using Magnetic Fields to Stimulate the Back to Treat Chronic Lower Back Pain.NCT07652944 · Not applicable · Joe X. Zhang · starts Jul 1, 2026
- Remibrutinib in Real-world Clinical Practice - a Germany Sub-study (REASSERT)NCT07642557 · Not reported · Novartis Pharmaceuticals · starts Aug 4, 2026
Approved 14
- DesloratadineHistamine H1 receptor antagonist
- OmalizumabIg epsilon chain C region inhibitor
- LevocetirizineHistamine H1 receptor antagonist
- FexofenadineHistamine H1 receptor antagonist
- CetirizineHistamine H1 receptor antagonist
- LoratadineHistamine H1 receptor antagonist
- ClemastineHistamine H1 receptor antagonist
- PromethazineHistamine H1 receptor antagonist
- CarbinoxamineHistamine H1 receptor antagonist
- CyproheptadineHistamine H1 receptor antagonist
- DexchlorpheniramineHistamine H1 receptor antagonist
- HydroxyzineHistamine H1 receptor antagonist
- EpinephrineAdrenergic receptor agonist
- Cromolyn
Phase 3 6
- DiphenhydramineHistamine H1 receptor antagonist
- RupatadinePlatelet activating factor receptor antagonist
- CholecalciferolVitamin D receptor agonist
- PrednisoneGlucocorticoid receptor agonist
- BilastineHistamine H1 receptor inverse agonist
- DoxepinNorepinephrine transporter inhibitor
Phase 2 11
- FenebrutinibTyrosine-protein kinase BTK inhibitor
- MethotrexateDihydrofolate reductase inhibitor
- Miltefosine
- CilostazolPhosphodiesterase 3A inhibitor
- Human immunoglobulin gReplacement therapy, immunomodulatory effects
- DupilumabInterleukin-4 receptor subunit alpha antagonist
- QuilizumabIg epsilon chain C region inhibitor
- AfamelanotideMelanocortin receptor 1 agonist
- LirentelimabSialic acid-binding Ig-like lectin 8 inhibitor
- BisoctrizoleSunscreen
- Titanium dioxide
Phase 1 or earlier 4
- AzathioprineAmidophosphoribosyltransferase inhibitor
- CyclosporineCyclophilin A modulator
- RituximabB-lymphocyte antigen CD20 binding agent
- BriquilimabStem cell growth factor receptor inhibitor
How its trials ended
249 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 69 whose ending is known, 48% met their primary endpoint, 4% missed it and 48% stopped early.
- Completed, result not reported11245%
- Ongoing4217%
- Met its primary endpoint3313%
- Status unknown2610%
- Stopped: other or unclear146%
- Stopped: enrollment or feasibility73%
- Stopped: sponsor or business decision62%
- Stopped: lack of efficacy52%
- Missed its primary endpoint31%
- Stopped: funding1<1%
| Feb 27, 2026 | A phase 3b long-term efficacy and safety extension study of barzolvolimab in participants with chronic spontaneous urticaria who have completed CDX0159-12 or…Barzolvolimab (CDX-0159) | Celldex Therapeutics Inc | Ongoing |
| Apr 2, 2025 | A randomized, double-blind, placebo controlled, dose-ranging study evaluating the efficacy and safety of EVO756 in adults with moderate to severe chronic…EVO756 | Evommune | Closed |
| Oct 10, 2024 | A phase 3 randomized, double-blind, placebo-controlled study to assess the efficacy and safety of barzolvolimab in patients with chronic spontaneous urticaria…Barzolvolimab (CDX-0159) | Celldex Therapeutics Inc | Ongoing |
| Oct 4, 2024 | A phase 3 randomized, double-blind, placebo-controlled study to assess the efficacy and safety of barzolvolimab in patients with chronic spontaneous urticaria…CDX-0159 | Celldex Therapeutics Inc | Ongoing |
| Aug 2, 2024 | An open-label extension study evaluating the safety, tolerability, pk, immunogenicity, and clinical response of multiple doses of iv AK006 in subjects with H1…AK006 | Allakos | Ongoing |
| Feb 8, 2024 | A phase 1, double-blind, randomized, placebo-controlled, sequential, singleand multiple- ascending dose study to evaluate the safety, tolerability, pk, and…AK006 | Allakos | Closed |
| Nov 20, 2023 | A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and…Remibrutinib (LOU064) | Novartis Pharmaceuticals | Ongoing |
| Aug 18, 2023 | A global, multicenter, randomized, double-blind, double-dummy, parallel-group, phase 3b study to assess the efficacy, safety, and tolerability of remibrutinib…Remibrutinib (LOU064) | Novartis Pharmaceuticals | Ongoing |
| Aug 15, 2023 | Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the effects of EP262 in subjects with chronic spontaneous urticariaEP262 | Escient Pharmceuticals Inc | Closed |
| Aug 10, 2023 | Phase 1b, open-label study to evaluate the safety, tolerability, and pharmacodynamics of EP262 in subjects with chronic inducible urticariaEP262 | Escient Pharmceuticals Inc | Closed |
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Dec 11, 2009 | AfamelanotideTreatment of solar urticaria | Clinuvel, Inc. | Designated |
| Apr 23, 2026 | RhapsidoRemibrutinib | Novartis Europharm Limited | EMA ↗ |
| Jan 13, 2012 | Desloratadine ActavisDesloratadine · generic | Actavis Group PTC ehf | EMA ↗ |
| Jan 13, 2012 | Desloratadine ratiopharmDesloratadine · generic | Ratiopharm GmbH | EMA ↗ |
| Nov 28, 2011 | DasseltaDesloratadine · generic | KRKA tovarna zdravil d.d. Novo mesto | EMA ↗ |
| Nov 24, 2011 | Desloratadine TevaDesloratadine · generic | Teva B.V | EMA ↗ |
| Jan 15, 2001 | AeriusDesloratadine | Organon N.V. | EMA ↗ |
| Jan 15, 2001 | NeoclaritynDesloratadine | Organon N.V. | EMA ↗ |
| Jan 15, 2001 | AzomyrDesloratadine | Organon N.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA